Abstract: Embodiments disclosed herein concern various cells, co-cultures, methods, systems, therapies, and treatments involving in vitro and in vivo generation and use of functional mammalian thymic tissue, thymus organs, and thymic organoids. In certain embodiments, cells, tissues, and organoids disclosed herein can be used to treat a subject having a thymic condition. In other embodiments, thymic cells and organoids produced by compositions and methods disclosed herein can be used to treat various conditions, diseases, and disorders, including auto-immune disorders, transplant rejections, cancer, or aging.

Abstract: The disclosed technology includes methods, systems, and devices for generating patient-specific functional thymic epithelial progenitor (TEP) cells. In some implementations, a method may include generating iPSCs from HSC; causing differentiation of the iPSC into thymic epithelial progenitor (TEP) cells, generating thymic epithelial cells by transplantation of the TEP cells into a host, wherein the TEP cells may differentiate into mature functional thymic epithelial cells (TECs). In some implementations, a system may include a cell population of patient specific cells, a population of iPSCs, a culture system for differentiating the iPSCs into a population of patient-specific TEP cells for transfer to a host or the patient to allow the TEP cells to differentiate into mature, functional TEC.